Patents Assigned to Wyeth
  • Publication number: 20080044410
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Application
    Filed: July 13, 2007
    Publication date: February 21, 2008
    Applicants: Wyeth, Cambridge Antibody Technology Limited
    Inventors: Geertruida Veldman, Monique Davies, Kening Song, Neil Wolfman, Kristie Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • Publication number: 20080045556
    Abstract: Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.
    Type: Application
    Filed: August 13, 2007
    Publication date: February 21, 2008
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Andrew Fensome, Gavin David Heffernan, Casey Cameron McComas, Richard Page Woodworth, Michael Byron Webb, Michael Anthony Marella, Edward George Melenski, Ronald Charles Bernotas
  • Patent number: 7332521
    Abstract: The present invention relates generally to substituted indoles such as substituted 1H-indole-2-carboxylic acid derivatives, and methods of using them.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: February 19, 2008
    Assignee: Wyeth
    Inventor: Baihua Hu
  • Patent number: 7332601
    Abstract: A method of generating synthetic metabolites of CCI-779 is provided. Five novel CCI-779 derivatives are described, as are methods of using these derivatives for detecting CCI-779 metabolites in samples.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: February 19, 2008
    Assignee: Wyeth
    Inventors: Ping Cai, Mark Ruppen, Russ Tsao
  • Patent number: 7332646
    Abstract: The present invention provides animal model systems for cartilage-degenerative disease, which comprise transgenic animals which can express recombinant matrix-degrading enzymes (MDEs), particularly matrix metalloproteinases (MMPs), in a temporally and spatially regulated manner. The invention also provides methods for producing phenotypic indicators of cartilage-degenerative disease in a mammal and methods for determining the potential of a composition to counteract cartilage-degenerative disease. The invention also provides isolated nucleic acids encoding proMMP polypeptides that exhibit constitutive enzymatic activity and isolated proMMP polypeptides.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: February 19, 2008
    Assignee: Wyeth
    Inventors: Lisa Ann Neuhold, Loran Marie Killar
  • Patent number: 7332174
    Abstract: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: February 19, 2008
    Assignees: Wyeth Holdings Corporation, The United States of America as represented by the Uniformed Services University of Health Sciences
    Inventors: Bruce A. Green, Randall K. Holmes, Michael G. Jobling, Duzhang Zhu
  • Patent number: 7332506
    Abstract: A compound represented by the formula I: wherein A represents the following heterocycles: and R1-9 are as defined herein, a composition containing this compound and methods for treating disorders of the serotonin-affected neurological systems utilizing such a compound or composition.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: February 19, 2008
    Assignee: Wyeth
    Inventors: Aranapakam M. Venkatesan, Jamie M. Davis, Yansong Gu
  • Publication number: 20080039639
    Abstract: Methods of preparing compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R1, R2, R3, R4, x, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
    Type: Application
    Filed: April 18, 2007
    Publication date: February 14, 2008
    Applicant: Wyeth
    Inventors: Alexander Gontcharov, Antonia Nikitenko, Panolil Raveendranath, Chia-Cheng Shaw, Bogdan Wilk, Dahui Zhou
  • Publication number: 20080038775
    Abstract: The invention relates to a novel method of inexpensively synthesizing large quantities of an essentially pure, biologically active, glycosylated Dkk protein, including mammalian and human Dkk proteins (e.g., human Dkk1). The invention further relates to the synthetically produced essentially purified, glycosylated and biologically active Dkk protein, and the characteristics of the protein.
    Type: Application
    Filed: March 23, 2005
    Publication date: February 14, 2008
    Applicants: WYETH, OSCIENT PHARMACEUTICALS CORPORATION
    Inventors: Kristina Allen, Anthony Anisowicz, Wei Chen, Girija Krishnamurthy, Matthew Olson
  • Publication number: 20080038777
    Abstract: Disclosed herein are polynucleotides encoding a chimeric C—C chemokine receptor 2B, the encoded polypeptides thereof, and methods of making and using said polynucleotides and polypeptides.
    Type: Application
    Filed: July 20, 2007
    Publication date: February 14, 2008
    Applicant: Wyeth
    Inventors: Brendan Bingham, Smita Kotnis, Jeffrey Kennedy
  • Publication number: 20080040819
    Abstract: Methods of identifying agents for treatment of schizophrenia and related disorders.
    Type: Application
    Filed: August 14, 2007
    Publication date: February 14, 2008
    Applicant: Wyeth
    Inventors: Brian BATES, Sheree Logue, Mark Pausch
  • Publication number: 20080039535
    Abstract: Methods of identifying agents for treatment of schizophrenia and related disorders.
    Type: Application
    Filed: August 14, 2007
    Publication date: February 14, 2008
    Applicant: Wyeth
    Inventors: Brian Bates, Sheree Logue, Mark Pausch
  • Patent number: 7329653
    Abstract: The present invention provides compounds of the general formulas: wherein Y is NR or —(CH2)n; R is H or alkyl; “Z” represents optionally substituted phenyl or a 6-membered aromatic ring having one nitrogen atom; “W” represents a optionally substituted phenyl or 5-membered aromatic ring having one nitrogen atom; “X” represents an optionally substituted 5-membered aromatic ring having one sulfur atom; as well as methods and pharmaceutical compositions utilizing these compounds for the inducing temporary delay of urination or treatment of disorders remedied by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: February 12, 2008
    Assignee: Wyeth
    Inventors: Amedeo A. Failli, Jay S. Shumsky, Thomas J. Caggiano, John P. Dusza, Kevin A. Memoli
  • Patent number: 7329663
    Abstract: The invention provides a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof and further provides a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: February 12, 2008
    Assignee: Wyeth
    Inventors: Mark R. Schmitt, Donald R. Kirsch, Jane E. Harris, Carl F. Beyer, Klaus-Jüergen Pees, Paul A. Carter, Waldemar Pfrengle, Guido Albert
  • Publication number: 20080033049
    Abstract: This invention provides estrogen receptor modulators having the structure: wherein R1 to R6 and R8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 28, 2007
    Publication date: February 7, 2008
    Applicant: Wyeth
    Inventors: Richard Mewshaw, Cuijian Yang
  • Publication number: 20080033175
    Abstract: This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline in an alcoholic solvent and a trialkylorthoformate to yield a 3-amino-2-cyanoacrylamide; combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride in acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 4-amino-3-quinolinecarbonitrile and also discloses a process for the preparation of a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile comprising combining a disubstituted 3-amino thiophene with a cyanoacetamide and trialkylorthoformate in an alcoholic solvent to obtain a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride and acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 7-amino-
    Type: Application
    Filed: October 5, 2007
    Publication date: February 7, 2008
    Applicant: Wyeth Holdings Corporation
    Inventors: Karen Sutherland, Gregg Feigelson, Diane Boschelli, David Blum, Henry Strong
  • Publication number: 20080031889
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Application
    Filed: January 23, 2007
    Publication date: February 7, 2008
    Applicant: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Publication number: 20080032299
    Abstract: Solid tumor prognosis genes, and methods, systems and equipment of using these genes for the prognosis and treatment of solid tumors. Prognosis genes for a solid tumor can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) are correlated with clinical outcome of the solid tumor. The prognosis genes of the present invention can be used as surrogate markers for predicting clinical outcome of a solid tumor in a patient of interest. These genes can also be used to select a treatment which has a favorable prognosis for the solid tumor of the patient of interest.
    Type: Application
    Filed: March 8, 2007
    Publication date: February 7, 2008
    Applicant: Wyeth
    Inventors: Michael Burczynski, Natalie Twine, William Trepicchio, Andrew Strahs, Fred Immermann, Donna Slonim, Andrew Dorner
  • Patent number: 7326700
    Abstract: The present invention provides tricyclic carboxamide compounds and methods and pharmaceutical compositions for their use in treatment, prevention, or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean deliver, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: February 5, 2008
    Assignee: Wyeth
    Inventors: Amedeo Arturo Failli, Eugene John Trybulski, Jay Scott Shumsky, William Jennings Sanders
  • Patent number: RE40086
    Abstract: The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: February 19, 2008
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph J. Hlavka, Phaik-Eng Sum, Yakov Gluzman, Ving J. Lee, Adma A. Ross